Treating rare bladder and testicular cancers with targeted therapy
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) for people with certain rare cancers of the urinary tract or testicles. The goal is to see if these treatments can shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these rare cancers: adenocarcinoma of the urinary tract, squamous cell carcinoma of the urinary tract, or testicular cancer that has not responded to other treatments.
- Your cancer must be advanced or have spread to other parts of the body.
- You need to have tumors that can be measured on scans.
- If you are in certain groups, you must have already had immunotherapy (like Keytruda) before. In other groups, you cannot have had it.
- You must be willing to provide a tissue sample from an earlier biopsy or have a fresh biopsy taken before starting treatment.
- Your kidneys, liver, and blood counts must be good enough based on standard lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
This trial tests a combination of two drugs—pembrolizumab (an immunotherapy) and enfortumab vedotin (a targeted therapy)—for people with collecting duct carcinoma or renal medullary carcinoma, two rare types of kidney cancer that have spread. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat bladder cancer that has grown into the muscle of the bladder. The goal is to shrink or eliminate the cancer so that surgery to remove the bladder may not be needed.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat muscle-invasive bladder cancer. The goal is to see if this can help patients avoid having their bladder removed. It is for people who cannot or choose not to have surgery.
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
Hear when a new Adenocarcinoma of the Bladder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.